Related Experiment Videos
Ras as a target in cancer therapy.
Rachel S Midgley1, David J Kerr
1CRC Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TT, Edgbaston, UK. Midgleyrs@cancer.bham.ac.uk
Critical Reviews in Oncology/Hematology
|November 5, 2002
Summary
Targeting Ras proteins, crucial in cancer cell growth, via farnesyl transferase inhibitors or immunotherapy shows promise. Inhibiting farnesylation halts Ras activity, reducing tumor growth, while mutations offer immunotherapy targets.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ras proteins are key regulators of cell growth and are frequently mutated in human cancers.
- Ras activation initiates downstream signaling pathways, including the Raf-1/mitogen-activated protein kinase pathway.
- Post-translational modifications, such as farnesylation, are essential for Ras protein function and membrane localization.
Purpose of the Study:
- To explore therapeutic strategies targeting Ras proteins in cancer.
- To evaluate the efficacy of farnesyl protein transferase (FPT) inhibitors.
- To investigate the potential of immunotherapy for Ras-mutated tumors.
Main Methods:
- Inhibition of farnesyl protein transferase (FPT) to block Ras post-translational modification.
- Assessment of anti-proliferative effects in vitro and in human cancer xenograft models.
- Evaluation of Ras mutations as neo-epitopes for T-cell recognition in immunotherapy.
Main Results:
- Farnesylation inhibition effectively ablates Ras activity, leading to significant anti-proliferative effects.
- FPT inhibitors are undergoing clinical trials (Phase I and II) with pharmacokinetic and dynamic assessments.
- Ras mutations can create neo-epitopes, making Ras-mutated tumors potential targets for immunotherapy.
Conclusions:
- Targeting Ras post-translational modification via FPT inhibitors is a rational therapeutic strategy.
- Immunotherapy targeting Ras mutations presents a novel approach for cancer treatment.
- Both FPT inhibition and immunotherapy warrant further clinical evaluation for Ras-driven cancers.